BRCA stands for BReast CAncer susceptibility gene. There are two BRCA genes - BRCA1 and BRCA2. The BRCA genes are called “tumor suppressor” genes. When functioning normally, these genes help the body prevent cancer.
Investigating BRCA mutational status in breast and ovarian cancer patients plays a double role. The first, is the identification of familiar cancer predisposition; the second, is address therapeutic choices.
4bases HR1 BRCA 1/2 is a clinically validated kit for the identification of both somatic and germline mutations in BRCA 1 and BRCA 2 genes using DNA from routinely available FFPE tissue or blood samples.
4bases HR1 kit to identify BRCA somatic and germline mutations from FFPE or frozen tissue samples. 4bases HR1 kit identifies patients with advanced ovariancancer who may be candidates for treatment with olaparib, a new targeted therapy for women with advanced ovarian cancer associated with defective BRCA genes. The analysis of both somatic and germline mutations from tissue samples (FFPE or frozen) allows oncologist to identify and treat 8-10% more patients than the only analysis for germline mutations.
4bases 4bases HR1 kit to identify BRCA germline mutations from blood samples. 4bases HR1 commercial kit assesses a person’s risk of developing hereditary breast or ovarian cancer based on the detection of mutations in the BRCA1 and BRCA2 genes. Knowing the results may help patients and their healthcare professionals either prevent or delay the onset of cancer or detect it at an earlier, more treatable stage.
“BRCA1 and BRCA2 are among the most frequently mutated genes in high-grade ovarian serous carcinoma, which is responsible for the vast majority of ovarian cancer deaths. Indeed, germline and somatic mutations in HR genes occur in about 30% of patients with ovarian carcinoma, of which up to 75% are in BRCA1 and BRCA2 genes. Patients carrying a germline or somatic BRCA1/BRCA2 mutation have been associated with a better prognosis and a better response to platinum-based therapy.“ Source: Mafficini A et al. Oncotarget. 2016 Jan 12;7(2):1076-83